Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus: Delving deeper

GLP-1 RA studies showed a macrovascular disease benefit.

Read More
CPD POINTS: 1

REWINDING REWARD in the management of type 2 diabetes

SGLT2-inhibitors have a major beneficial effect on reducing heart failure

Read More
CPD POINTS: 1

Combining for effective simplicity

In this article we will look at key lessons learned from landmark studies.

Read More
CPD POINTS: 1

Specialist Forum October 2021 issue CPDs

Below you will find links to CPD articles produced for Specialist Forum‘s October 2021 issue.

Read More
CPD POINTS: 3

Superior HbA1c reduction with Solimix

Type 2 diabetes (T2DM) is a progressive disease, associated with microvascular complications such as retinopathy, nephropathy, and neuropathy, as well…

Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus

Dr Nqoba Tsabedze, Academic & Clinical Head – Division of Cardiology, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand 

Read More
CPD POINTS: 1

Controlling blood sugar levels optimally

Type 2 diabetes (T2DM) is a major global public health problem. According to the World Health Organisation, about 422 million…

Empagliflozin and metformin to reduce cardiac risk in type 2 diabetes?

Type 2 diabetes is a major risk factor for cardiovascular disease. Having both type 2 diabetes and cardiovascular disease increases…

The challenge of diabetes management in LMICs

In low-and middle-income countries, especially in Sub-Saharan Africa, noncommunicable diseases (NCDs) such as diabetes are placing a growing strain on…

Read More
CPD POINTS: 1

Achieving optimal glycaemic control with insulin lispro pens

A rise in body weight or worsening insulin tolerance in diabetic patients nearly always results in an increase in their…

Read More
CPD POINTS: 1

New hope for obesity patients

Liraglutide, which has consistently shown 5%-10% of weight-loss when combined with diet and physical activity, has been given the go-ahead…

Read More
CPD POINTS: 3

T2DM management simplified

Type 2 diabetes (T2DM) has attained the status of a global pandemic, spreading from affluent industrialised nations to emerging economies…

Osteoporosis an overlooked disease in diabetes

Over the past few years, evidence shows that people with diabetes are at extremely high risk of osteoporosis and fracture.…

Could dulaglutide reduce the T2DM burden?

Let’s face it, with public health crises popping up out of nowhere lately, the last thing the healthcare system needs…

Read More
CPD POINTS: 1

Changing the diabetes paradigm

Figures from 2019 indicate that one in 11 adults (20-79 years) – or an estimated 463 million people worldwide have…

Dulaglutide is an ‘engineering feat’ in T2DM treatment

The goal of type 2 diabetes (T2DM) treatment is not only to promote glucose lowering, but also to prevent glycaemic…

Lowering glucose, preventing glycaemic variability equally important in T2DM treatment

The goal of type 2 diabetes (T2DM) treatment is not only to promote glucose lowering, but also to prevent glycaemic…

Read More
CPD POINTS: 2

Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30

Approximately 1.6 billion people worldwide are Muslims. Ramadan is the ninth month of the Islamic calendar, and fasting (total abstinence…

Basal insulin in patients who fast during Ramadan

A real-world study has evaluated a second-generation basal insulin used alongside IDF-DAR guidelines. The results contrast with literature reports of…

Diabetes and COVID-19

How do we manage diabetic patients in an age of COVID-19, given the increased risk of mortality experienced by diabetic…

Read More
CPD POINTS: 1
« » page 1 / 3